The US health secretary's cancellation of nearly $500 million worth of funding for multiple mRNA vaccine projects is a dangerous decision for public health, experts have warned.
Robert F. Kennedy Jr, a long-standing vaccine sceptic, said there would be a "coordinated wind-down" of research into mRNA vaccines, which protect against respiratory viruses such as Covid-19, influenza and H5N1 bird flu.
What are mRNA vaccines? First used at scale during the Covid pandemic, mRNA vaccines prompt the body to make "a harmless piece of protein" that is otherwise "identical to one found in a particular virus or bacterium", said the UK Health Security Agency. "Our immune system recognises it as a foreign body" and starts to produce defensive antibodies.
This type of vaccine can be produced, modified and distributed much more quickly than traditional vaccines – one of the key reasons why it has "long been distrusted by vaccine sceptics", said The New York Times.
Why is Kennedy cutting funding? Kennedy referred to mRNA technology as "troubled" and called older "whole-cell" vaccine technology "safer". He also claimed that "mRNA vaccines don't perform well against viruses that infect the upper respiratory tract" – a "wildly incorrect statement", Brown University pandemic preparedness expert Jennifer Nuzzo told The New York Times.
What does it mean for health? Experts in vaccine research say the funding cut is a "real blow" to efforts to prepare for the next pandemic and will leave the US "further behind in developing new vaccines", said Vox.
And if "one of the largest markets in the world" decides not to invest in mRNA, manufacturers "will be less willing to invest their own resources in the technology", said Andrew Pollard, who led the development of the Oxford-AstraZeneca Covid vaccine as director of the Oxford Vaccine Group. The "wider implications of this decision could be that the world is less safe", he told The Guardian.
But on a positive note, the UK is collaborating with two firms working on mRNA technologies, Kate Bingham, who led the UK's vaccine taskforce during the early part of the Covid pandemic, told the paper. The UK has also invested in a new £26.4 million RNA Centre of Excellence to develop new mRNA therapies and vaccines. |